You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The companies plan to market an HIV rapid test using a single drop of blood that leverages Atomo's lateral-flow platform and Access Bio's rapid test.
The project relates to an NGS-based clinical trial assay associated with a sponsored project agreement between Qiagen and an undisclosed pharmaceutical company.
Under the agreement, new companion diagnostics will be included in updates to FoundationOne CDx, which was recently FDA approved.
Qualified patients will have immediate access to IQuity's MS test, with expected access later to an IBD-IBS test, and a fibromyalgia test.
The two companies have signed a new master collaboration agreement under which HTG will develop custom assays for use in earlier stages of Merck's drug development process.
The Mayo Clinic will apply PathoQuest's next-generation sequencing-based iDtect Blood test in a study to identify febrile neutropenia in patients.
The drugmaker is subsidizing the cost of BRCA testing for women diagnosed with ovarian cancers, for whom guidelines now recommend such testing for cancer therapy selection.
Thorne Research will receive exclusive rights to distribute and commercialize future Drawbridge Health products in the US.
Roche's CDx would help Inotrem identify suitable patients for a new therapy it's developing for septic shock, and help physicians identify patients at the highest risk of death.
The hospital will run Agendia's new NGS test kit in its lab, comparing results with the firm's existing centralized MammaPrint test.